NCT05109520View on ClinicalTrials.gov

Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL

CompletedOBSERVATIONAL

Enrollment

867

Participants

Timeline

Start Date

September 8, 2021

Primary Completion Date

October 14, 2021

Study Completion Date

October 14, 2021

Conditions

Type 1 Diabetes

Interventions

DRUG

Insulin Glargine 300 UNT/ML [Toujeo]

Switch during standard routine care to Gla-300.

Trial Locations (3)

2650

Universitair Ziekenhuis Antwerpen, Edegem

3000

Universitaire Ziekenhuizen Leuven, Leuven

9300

Onze Lieve Vrouw Ziekenhuis Aalst, Aalst

All Listed Sponsors

collaborator

University Hospital, Antwerp

OTHER

collaborator

Onze Lieve Vrouw Hospital

OTHER

lead

prof dr Pieter Gillard

OTHER

NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL | Biotech Hunter | Biotech Hunter